Catalog No.
DVV03109
Expression system
Mammalian Cells
Species reactivity
Human immunodeficiency virus 1 (HIV-1)
Isotype
VHH-8His-Cys-tag
Clonality
Monoclonal
Target
Envelope glycoprotein gp160, Env polyprotein, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, Glycoprotein 41, gp41, env
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
Q03805
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
m36.4
Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120., PMID:40433366
Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimer., PMID:40339576
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial., PMID:38916429
Methamphetamine enhancement of HIV-1 gp120-mediated NLRP3 inflammasome activation and resultant proinflammatory responses in rat microglial cultures., PMID:38168345
Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy-Treated Individuals With Undetectable Viremia., PMID:38035854
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120., PMID:37795976
Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability., PMID:37260254
Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity., PMID:36961924
Aptamer-linked photonic crystal hydrogel sensor for rapid point-of-care detection of human immuno-deficiency virus-1 (HIV-1)., PMID:36827736
Myomedin replicas of gp120 V3 loop glycan epitopes recognized by PGT121 and PGT126 antibodies as non-cognate antigens for stimulation of HIV-1 broadly neutralizing antibodies., PMID:36569830
The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection., PMID:32636304
Role of nanoscale antigen organization on B-cell activation probed using DNA origami., PMID:32601450
HIV gp120 Induces the Release of Proinflammatory, Angiogenic, and Lymphangiogenic Factors from Human Lung Mast Cells., PMID:32375243
Schwann cell-derived CXCL1 contributes to human immunodeficiency virus type 1 gp120-induced neuropathic pain by modulating macrophage infiltration in mice., PMID:32229220
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans., PMID:31999736
Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine., PMID:31634193
Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles., PMID:31515132
Interferon-β induced in female genital epithelium by HIV-1 glycoprotein 120 via Toll-like-receptor 2 pathway acts to protect the mucosal barrier., PMID:29553138
Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization., PMID:28834745
The glycan-mediated mechanism on the interactions of gp120 with CD4 and antibody: Insights from molecular dynamics simulation., PMID:28632942
IFNβ Protects Neurons from Damage in a Murine Model of HIV-1 Associated Brain Injury., PMID:28425451
Host Immune Responses in HIV-1 Infection: The Emerging Pathogenic Role of Siglecs and Their Clinical Correlates., PMID:28386256
Unsupervised selection of RV144 HIV vaccine-induced antibody features correlated to natural killer cell-mediated cytotoxic reactions., PMID:28268960
Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1., PMID:27908641
Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody., PMID:27449907
Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding., PMID:26902223
A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo., PMID:26516768
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition., PMID:26180102
Mass spectrometry approach and ELISA reveal the effect of codon optimization on N-linked glycosylation of HIV-1 gp120., PMID:25285362
A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy., PMID:24935650
A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism., PMID:24802758
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1., PMID:24614107
Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector., PMID:24098600
Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer., PMID:23757493
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG., PMID:23661056
Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine., PMID:23089396
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape., PMID:22693447
X4 Human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4., PMID:22479424
Regulation of P-glycoprotein by human immunodeficiency virus-1 in primary cultures of human fetal astrocytes., PMID:21826700
HIV-1 gp120-induced axonal injury detected by accumulation of β-amyloid precursor protein in adult rat corpus callosum., PMID:21286834
Generation of anti-DC-SIGN monoclonal antibodies capable of blocking HIV-1 gp120 binding and reactive on formalin-fixed tissue., PMID:21078343
Activation of p38 MAPK is required in monocytic and neuronal cells for HIV glycoprotein 120-induced neurotoxicity., PMID:20855878
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1., PMID:20616233
beta-Chemokine production by neural and glial progenitor cells is enhanced by HIV-1 Tat: effects on microglial migration., PMID:20403075
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand., PMID:19843557
[Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies]., PMID:19409660
The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes., PMID:19349871
CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth., PMID:19139127
NMR evidence of charge-dependent interaction between various PND V3 and CCR5 N-terminal peptides., PMID:19117029
Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region., PMID:17709529
For research use only. Not for human or drug use.
